Nature Reviews Endocrinology

Article	Citations
COVID-19 and diabetes mellitus: from pathophysiology to clinical management	630
Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure	441
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19	319
Exerkines in health, resilience and disease	301
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic	290
Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)	257
Mitochondrial and metabolic dysfunction in ageing and age-related diseases	256
The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases	251
The burden and risks of emerging complications of diabetes mellitus	249
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus	227
Current understanding of the molecular and cellular pathology of diabetic retinopathy	219
Diet and exercise in the prevention and treatment of type 2 diabetes mellitus	214
Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics	209
Type 2 diabetes mellitus in older adults: clinical considerations and management	200
The health effects of vitamin D supplementation: evidence from human studies	193
Tracking placental development in health and disease	179
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus	176
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease	175
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy	171
Endocrine toxicities of immune checkpoint inhibitors	169
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus	168
Autophagy in metabolic disease and ageing	164
Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver	156
Current practice in patients with differentiated thyroid cancer	156
Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer	149

Nearly a decade on — trends, risk factors and policy implications in global obesity	143
International consensus on the diagnosis and management of dumping syndrome	129
Will the COVID-19 pandemic worsen the obesity epidemic?	126
Environmental factors in declining human fertility	126
Metabolic regulation of kisspeptin — the link between energy balance and reproduction	113
Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus	109
Clinical application of intermittent fasting for weight loss: progress and future directions	109
Creatine metabolism: energy homeostasis, immunity and cancer biology	106
Exercise adaptations: molecular mechanisms and potential targets for therapeutic benefit	99
Paracetamol use during pregnancy — a call for precautionary action	96
The role of insufficient sleep and circadian misalignment in obesity	94
Metabolic pathways in obesity-related breast cancer	91
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD	91
New insights into KATP channel gene mutations and neonatal diabetes mellitus	88
Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy	84
Epigenetic inheritance of polycystic ovary syndrome — challenges and opportunities for treatment	82
The evolving view of thermogenic adipocytes — ontogeny, niche and function	80
Macrophage functional diversity in NAFLD — more than inflammation	80
Tuning fatty acid oxidation in skeletal muscle with dietary fat and exercise	77
Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus	77
International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers	76
The importance of the RET gene in thyroid cancer and therapeutic implications	73
Brain insulin signalling in metabolic homeostasis and disease	73
Metformin: update on mechanisms of action and repurposing potential	73
Novel therapies with precision mechanisms for type 2 diabetes mellitus	71
Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis	70
Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations	69
Understanding the ever-changing incidence of thyroid cancer	69
Clinical aspects of multiple endocrine neoplasia type 1	67
Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions	66
Pathogenesis and treatment of primary aldosteronism	65
Lipid droplet biogenesis and functions in health and disease	63
Aggressive pituitary tumours and pituitary carcinomas	62
The physiological role of β-cell heterogeneity in pancreatic islet function	62
Cellular and molecular features of EDC exposure: consequences for the GnRH network	61
Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus	60
Functions of galanin, spexin and kisspeptin in metabolism, mood and behaviour	60
Primary hypothyroidism and quality of life	59
Adaptive immune cells shape obesity-associated type 2 diabetes mellitus and less prominent comorbidities	58
Targeting lipid GPCRs to treat type 2 diabetes mellitus — progress and challenges	55
Assessment and treatment of thyroid disorders in pregnancy and the postpartum period	53
One hundred years of insulin therapy	52
Managing fragility fractures during the COVID-19 pandemic	50
Metabolic implications of pancreatic fat accumulation	50
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1	50
Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies	49
The role of biomineralization in disorders of skeletal development and tooth formation	48
Hormonal regulation of biomineralization	48
Metabolic disorders, COVID-19 and vaccine-breakthrough infections	48
The role of stress kinases in metabolic disease	46

Uterine bleeding: how understanding endometrial physiology underpins menstrual health	46
The multiple roles of life stress in metabolic disorders	46
Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia	45
Hepatic sexual dimorphism — implications for non-alcoholic fatty liver disease	45
The gut microbiota in obesity and weight management: microbes as friends or foe?	45
The role of iron in host–microbiota crosstalk and its effects on systemic glucose metabolism	45
Hormonal regulation of mammary gland development and lactation	43
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement	43
Optoacoustic imaging in endocrinology and metabolism	43
Treating menopause — MHT and beyond	42
Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine	42
International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia	42
Skeletal disorders associated with the growth hormone–insulin-like growth factor 1 axis	41
Multifaceted actions of melanin-concentrating hormone on mammalian energy homeostasis	41
Global accessibility of therapeutics for diabetes mellitus	41
Multikinase inhibitors in thyroid cancer: timing of targeted therapy	40
The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits	40
The trials and tribulations of determining HbA1c targets for diabetes mellitus	40
Management challenges and therapeutic advances in congenital adrenal hyperplasia	39
A global view of hypertensive disorders and diabetes mellitus during pregnancy	38
Unravelling the role of epigenetics in reproductive adaptations to early-life environment	37
Epigenetics of type 2 diabetes mellitus and weight change — a tool for precision medicine?	37
Long COVID — metabolic risk factors and novel therapeutic management	37
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases	35
Advances in differential diagnosis and management of growth hormone deficiency in children	34
The role of regulated necrosis in endocrine diseases	34
Adrenal cortex renewal in health and disease	33
Primary aldosteronism — a multidimensional syndrome	32
Modelling metabolic diseases and drug response using stem cells and organoids	30
Intermuscular adipose tissue in metabolic disease	29
Challenges in the care of transgender and gender-diverse youth: an endocrinologist’s view	29
Exercise in adults with type 1 diabetes mellitus	28
Skeletal and extraskeletal disorders of biomineralization	27
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice	26
The emerging osteo-metabolic phenotype of COVID-19: clinical and pathophysiological aspects	26
SGLT2 inhibitors in people with and without T2DM	25
Potential gut–brain mechanisms behind adverse mental health outcomes of bariatric surgery	25
The interplay between diabetes mellitus and menopause: clinical implications	25
The importance of metabolic dysfunction in polycystic ovary syndrome	24
Insights into non-classic and emerging causes of hypopituitarism	24
Machine intelligence in non-invasive endocrine cancer diagnostics	24
Consensus Statement on the definition and classification of metabolic hyperferritinaemia	22
Revisiting the role of inflammation in the loss of pancreatic β-cells in T1DM	21
COVID-19 alters thinking and management in metabolic diseases	21
X chromosome agents of sexual differentiation	21
Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia	21
The G protein-coupled oestrogen receptor GPER in health and disease: an update	21
Immune dysfunction in developmental programming of type 2 diabetes mellitus	21
Type 2 diabetes mellitus in sub-Saharan Africa: challenges and opportunities	20
Who would have thought — myokines two decades on	20
Primary bilateral macronodular adrenal hyperplasia: definitely a genetic disease	19
Strategies for modelling endometrial diseases	19
Heterogeneity and endotypes in type 1 diabetes mellitus	19
Exosomes as novel biomarkers in metabolic disease and obesity-related cancers	18
Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation	18
Is there a role for the adrenal glands in long COVID?	17
Lactate as a major myokine and exerkine	17
Metabolic determinants of tumour initiation	17
Towards a better understanding of diabetes mellitus using organoid models	17
Severe COVID-19 outcomes — the role of physical activity	17
Diagnostic and therapeutic advances in neuroendocrine tumours	17
Transplantation of stem cell-derived pancreatic islet cells	16
An integrated model of obesity pathogenesis that revisits causal direction	16
High resolution 3D structures of mineralized tissues in health and disease	16
How can social jetlag affect health?	16
The role of ChREBP in carbohydrate sensing and NAFLD development	15
Long-term and sequential treatment for osteoporosis	15
The MMP14–caveolin axis and its potential relevance for lipoedema	15
The regulation of endocrine-disrupting chemicals to minimize their impact on health	14
Sex hormones in SARS-CoV-2 susceptibility: key players or confounders?	13
Adipose tissue in communication: within and without	13
Progress in islet transplantation is more important than ever	12
Fetoplacental oxygen homeostasis in pregnancies with maternal diabetes mellitus and obesity	12
Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer	12
Metabolism and exercise: the skeletal muscle clock takes centre stage	12
Mammalian models of diabetes mellitus, with a focus on type 2 diabetes mellitus	12
SARS-CoV-2 fires up inflammation in adipose tissue	12
A spectacular year for islet and stem cell transplantation	11
The emerging evidence for non-skeletal health benefits of vitamin D supplementation in adults	11
Why does the immune system destroy pancreatic β-cells but not α-cells in type 1 diabetes?	11

Programming of metabolism by adipokines during development	11
Improving clinical outcomes through attention to sex and hormones in research	11
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus	11